OnKure Therapeutics (OKUR) Competitors

OnKure Therapeutics (NASDAQ:OKUR) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.

Which has more volatility and risk, OKUR or IFRX?

OnKure Therapeutics has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Is OKUR or IFRX more profitable?

OnKure Therapeutics has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. OnKure Therapeutics' return on equity of -51.17% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
InflaRx	-33,362.70%	-65.98%	-56.86%

Do insiders & institutionals have more ownership in OKUR or IFRX?

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in OKUR or IFRX?

InflaRx received 236 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 65.24% of users gave InflaRx an outperform vote.

Company	Underperform	Outperform
OnKure Therapeutics	Outperform Votes 8 100.00%	Underperform Votes No Votes
InflaRx	Outperform Votes 244 65.24%	Underperform Votes 130 34.76%

Which has stronger valuation & earnings, OKUR or IFRX?

InflaRx has higher revenue and earnings than OnKure Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$77.39M	-$5.26	-0.42
InflaRx	$129.75K	876.98	-$46.18M	-$0.82	-2.07

Does the media prefer OKUR or IFRX?

In the previous week, OnKure Therapeutics had 5 more articles in the media than InflaRx. MarketBeat recorded 6 mentions for OnKure Therapeutics and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.59 beat OnKure Therapeutics' score of 0.38 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate OKUR or IFRX?

OnKure Therapeutics currently has a consensus price target of $32.33, indicating a potential upside of 1,346.68%. InflaRx has a consensus price target of $8.50, indicating a potential upside of 401.47%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33
InflaRx	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

OnKure Therapeutics beats InflaRx on 10 of the 17 factors compared between the two stocks.